A recent large-scale study aiming to score specific risks for heterozygous ATM variant carriers demonstrated moderate-to-high risks for pancreatic, prostatic, gastric, and female invasive ductal breast malignancies and low-to-moderate risks for breast ductal carcinoma in situ, male breast cancer, ovarian cancer, colorectal cancer, and melanoma [11]. This evidence concerns the gene ATM and ovarian carcinoma.